Cabozantinib

(Cometriq®)

Cabozantinib

Latest News

loading GIF

Drug updated on 4/15/2024

Dosage FormCapsule (oral; 20 mg, 80 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Cabozantinib S-Malate (Cometriq) is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer and has also been used to treat advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer that is radioactive iodine refractory, and Merkel cell carcinoma.
  • A total of 10 studies were reviewed which provided information on the safety and efficacy of Cabozantinib in comparison to other medications such as Sorafenib and Lenvatinib.
  • In terms of comparative efficacy and safety against Sorafenib or Lenvatinib in differentiated thyroid cancer (DTC), Cabozantinib could be a valuable second-line option due to limitations in effective targeted therapies for patients with certain mutations.
  • When combined with other therapies, Cabozantinib showed promising results by improving progression-free survival across different solid tumors including renal cell carcinoma and non-small-cell lung cancer while maintaining a consistent toxicity profile.
  • The adverse effects associated with Cometriq include hypertension, diarrhea, fatigue, along with rare cases showcasing cardiotoxicity, marking an uncommon but concerning side effect requiring monitoring of cardiovascular health during treatment. There's a high occurrence rate of grade 3 or higher adverse events, particularly when compared to Lenvatinib, suggesting a significant but manageable toxicity profile.
  • While specific population considerations were not detailed exhaustively, one mention suggested broader applicability across older populations based on an 83-year-old patient responding well to Cabozantinib for MCC alongside MTC.

Product Monograph / Prescribing Information

Document TitleYearSource
Cometriq (cabozantinib) Prescribing Information.2020Exelixis, Inc. Alameda, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines